Minocycline in Stroke Study at Maimonides

NCT ID: NCT07237048

Last Updated: 2026-01-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 1164 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2028-12-31

Brief Summary

The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.

The main questions it aims to answer are:

1. Does Minocycline improve *National Institutes of Health Stroke Scale* (NIHSS) scores at hospital discharge and 90 days post-stroke?

2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -*Modified Rankin Scale* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care?

Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality.

Participants will:

1. Be randomly assigned by block to receive either:

Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only

2. Undergo neurological assessments using NIHSS *National Institutes of Health Stroke Scale* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke

3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses

NIHSS: *National Institutes of Health Stroke Scale*, which is stroke severity scale,

mRS: *Modified Rankin Scale*, which is stroke disability scale

Detailed Description

Stroke is a major cause of death and disability in the United States. While treatments such as clot-busting drugs (tPA or TNK) and thrombectomy can help some patients with ischemic strokes, there are limited options for protecting the brain after a stroke. Minocycline is a low-cost antibiotic that may have protective effects on the brain due to its anti-inflammatory and neuroprotective properties.

At Maimonides Medical Center, we have used Minocycline for all eligible patients with acute strokes in clinical practice until March 2019, Studies found that Minocycline was associated with better stroke outcomes and lower death rates, especially in patients with moderate stroke severity. However, no large, randomized trial has yet confirmed its benefits.

This study will prospectively enroll 1,164 adults with moderate stroke (National Institutes of Health Stroke Scale 5-20) within 24 hours of symptom onset. Participants will be assigned by block randomization to receive either:

Minocycline 200 mg orally once daily for 5 days + standard stroke care, or Standard stroke care alone.

The study will measure stroke severity (using the *NIHSS*- National Institutes of Health Stroke Scale) and disability (using the mRS - *modified Rankin Scale*) at hospital discharge, 30 days, and 90 days. It will also monitor for death and any bleeding complications in the brain.

The goal is to see whether Minocycline, in addition to usual care, can safely improve recovery and survival in people with acute stroke. The results could help guide future stroke treatment nationwide.

NIHSS: *National Institutes of Health Stroke Scale*, is stroke severity scale, mRS: *Modified Rankin Scale*, is stroke disability scale, WHO: *World Health Organization*

Conditions

Stroke; Ischemia Stroke; Hemorrhagic Strokes; Mortality; Morbidity; Cerebrovascular Accident (Stroke); Intracerebral Haemorrhage (ICH)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Standard Stroke Care without Minocycline

582 Patients in this arm will receive standard stroke care, No Minocycline will be given

Group Type: NO_INTERVENTION

No interventions assigned to this group

Standard Stroke Care with Minocycline

582 patients in the Minocycline arm will receive Minocycline 200 mg every 24 hours for five days with standard stroke care

Group Type: EXPERIMENTAL

Minocycline 200mg

Intervention Type: DRUG

Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.

Interventions

Minocycline 200mg

Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.

Intervention Type: DRUG

Other Intervention Names

Minocin; Minocycline hydrochloride

Eligibility Criteria

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Age >/=18

2. NIHSS 5-20 *National Institutes of Health Stroke Scale*

3. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO *(World Health Organization) * guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed

4. The onset of neurological symptoms less than 24 hours

Exclusion Criteria

An individual who meets any of the following criteria is excluded from participation in this study:

1. Clinically stroke is not suspected

2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline

3. Pregnancy or suspected pregnancy or breastfeeding

4. Previous history of intolerance to Minocycline

5. Acute or chronic renal failure (stage III with GFR *(Glomerular Filtration Rate) * or Creatinine threshold)

6. Any patients with contraindications to undergo CT (Computed Tomography) / MRI (Magnetic Resonance Imaging)

7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission

8. Pre-existing infectious disease requiring antibiotics

9. Inability to tolerate enteral medications/feeds

10. Patient/ family refusal

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Joyce Chen

OTHER

Sponsor Role: lead

Responsible Party

Joyce Chen

Clinical Data Analyst

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Qingliang T. Wang, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Maimonides Medical Center

Central Contacts

Qingliang T. Wang, MD, PhD

Role: CONTACT

qwang@maimo.org

718.283.7670

Ilya Levin, DO

Role: CONTACT

718.283.8681

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Internal Stroke Research Funds

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2024-05-01-MMC

Identifier Type: -

Identifier Source: org_study_id